Keryx Biopharmaceuticals, Inc. to Conduct Conference Call to Discuss KRX-0401 (Perifosine) Clinical Development Program in Color
January 27 2010 - 4:00PM
PR Newswire (US)
Conference Call to Be Held Tomorrow, Thursday, January 28th, at
9:00am ET NEW YORK, Jan. 27 /PRNewswire-FirstCall/ -- Keryx
Biopharmaceuticals, Inc. (NASDAQ:KERX) will conduct a conference
call to discuss the updated Phase 2 results on the clinical
activity of KRX-0401 (perifosine), the Company's PI3K/Akt pathway
inhibitor for cancer, in combination with capecitabine (Xeloda®) as
a treatment for advanced, metastatic colorectal cancer. The
conference call will take place tomorrow, Thursday, January 28,
2010, at 9:00am EST. Ron Bentsur, CEO of Keryx Biopharmaceuticals,
will host the call. Joining Mr. Bentsur on the call will be Dr.
Johanna Bendell, Director, GI Oncology Research and Assoc.
Director, Drug Development Unit, Sarah Cannon Research Institute,
and Dr. Paulo Hoff, Professor of Medicine and Chairman of Medical
Oncology at the University of Sao Paulo, Brazil, and former lead
investigator for the capecitabine (Xeloda®) Phase 3 approval study
in metastatic colorectal cancer. CONFERENCE CALL INFORMATION:
Interested parties may participate in the call by dialing
1-888-596-2611 (U.S.), 1-913-312-1432 (outside the U.S.), call-in
ID: KERYX. The audio recording of the conference call will be
available for replay at http://www.keryx.com/, for a period of 15
days after the call. A copy of the poster is available via request
to Keryx. Perifosine is currently in a Phase 3 trial, under Special
Protocol Assessment (SPA), for the treatment of relapsed/refractory
multiple myeloma. KRX-0401 (perifosine) is in-licensed by Keryx
from Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) in the United
States, Canada and Mexico. About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development
and commercialization of medically important pharmaceutical
products for the treatment of life-threatening diseases, including
cancer and renal disease. Keryx is developing KRX-0401
(perifosine), a novel, potentially first-in-class, oral anti-cancer
agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt
pathway, a key signaling cascade that has been shown to induce cell
growth and cell transformation. KRX-0401 has demonstrated both
safety and clinical efficacy in several tumor types, both as a
single agent and in combination with novel therapies. KRX-0401 also
modulates a number of other key signal transduction pathways,
including the JNK pathway, which are pathways associated with
programmed cell death, cell growth, cell differentiation and cell
survival. KRX-0401 is currently in a Phase 3 trial, under Special
Protocol Assessment (SPA), in multiple myeloma, and in Phase 2
clinical development for several other tumor types. Keryx is also
developing Zerenex(TM) (ferric citrate), an oral, iron-based
compound that has the capacity to bind to phosphate and form
non-absorbable complexes. The Phase 3 clinical program of Zerenex
in the treatment for hyperphosphatemia (elevated phosphate levels)
in patients with end-stage renal disease is expected to begin this
quarter under an SPA agreement with the FDA. Keryx is headquartered
in New York City. KERYX CONTACT: Lauren Fischer Director, Investor
Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5962
DATASOURCE: Keryx Biopharmaceuticals, Inc. CONTACT: Lauren Fischer,
Director, Investor Relations, Keryx Biopharmaceuticals, Inc.,
+1-212-531-5962 Web Site: http://www.keryx.com/
Copyright